Objective: In our study, anxiety level and quality of life were determined in patients with CSU and the variables affecting these two factors were analyzed.

Materials and Methods: This cross-sectional study was conducted using face-to-face interviews with 66 patients who were diagnosed with CSU and admitted to the Dermatology Clinic of Adana City Training and Research Hospital in 2023.

Results: 78.8% of the participants were female, the mean age was 40.22±12.82 years, and the mean duration of the disease was 5.36±6.05 years. The mean Urticaria Control Test (UCT) was 8.80±4.90, and 95.8% of the participants with good disease control received Omalizumab treatment (p=0.000). Participants with poorly controlled disease had a higher total score on the Beck Anxiety Scale (BAS) (11.40±7.41). The mean total score of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) was calculated as 45.17±15.52.

Conclusion: The findings of our study reveal the relationship between impaired quality of life and anxiety levels with disease activity in patients with CSU. Even if not life-threatening from the patient’s perspective, the uncertainty of symptoms is uncomfortable and limits daily life. New generation drugs such as omalizumab may positively affect quality of life.